Teleflex Receives FDA Clearance for 150 cm Length Arrow® GPSCath® Balloon Dilatation Catheters
July 29 2014 - 7:00AM
Business Wire
PTA balloon catheters combine angioplasty with
targeted injection system in a single device for use in below the
knee procedures.
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical devices for critical care and surgery, has announced that
its subsidiary Hotspur Technologies, Inc. received FDA 510(k)
clearance to market the Arrow® GPSCath® Balloon Dilatation
Catheters designed for use with .014” guide wires and in 150 cm
length. These novel products enable a variety of peripheral
vascular procedures to be performed below the knee with one dual
function catheter, potentially reducing procedure time, radiation
dosage, and expense for both patients and medical
professionals.
The Arrow® GPSCath® Balloon Dilatation Catheter is the first
dual functional balloon dilatation catheter that combines
angioplasty with the proprietary VisioValve™ Injection System. This
innovative combination enables physicians to perform peripheral
below the knee angioplasty and inject physician selected fluids,
such as contrast media, while maintaining guide wire position.
“With this latest product approval we continue our commitment to
enabling medical professionals to perform peripheral access
procedures that simplify and improve the doctor and patient
experience while reducing health care costs,” said Benson Smith,
Chairman, President & CEO of Teleflex. Added Smith, “We are
excited to bring this innovative product for use in below the knee
peripheral interventions to the market.”
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical
devices for a range of procedures in critical care and surgery. Our
mission is to provide solutions that enable healthcare providers to
improve outcomes and enhance patient and provider safety.
Headquartered in Wayne, PA, Teleflex employs approximately 11,400
people worldwide and serves healthcare providers in more than 150
countries. Additional information about Teleflex can be obtained
from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, GPSCath, Hotspur and VisioValve are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates. ©
2014 Teleflex Incorporated. All rights reserved. MC-000259
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor
Relations610-948-2836jake.elguicze@teleflex.comwww.teleflex.com
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024